Kadmon (NYSE:KDMN) Trading Up 5.6%

Kadmon Holdings Inc (NYSE:KDMN) shares were up 5.6% on Friday . The stock traded as high as $4.70 and last traded at $4.54, approximately 2,704,024 shares traded hands during trading. An increase of 43% from the average daily volume of 1,889,527 shares. The stock had previously closed at $4.30.

Several research analysts have recently weighed in on KDMN shares. ValuEngine raised shares of Kadmon from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Zacks Investment Research raised shares of Kadmon from a “sell” rating to a “hold” rating in a report on Wednesday. Nomura began coverage on shares of Kadmon in a report on Friday, January 10th. They set a “buy” rating and a $10.00 target price for the company. Finally, Cantor Fitzgerald upped their target price on shares of Kadmon from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $9.80.

The firm has a market capitalization of $546.00 million, a PE ratio of -4.41 and a beta of 2.48. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of 0.54. The stock’s fifty day simple moving average is $4.58 and its 200 day simple moving average is $3.20.

Kadmon (NYSE:KDMN) last announced its earnings results on Thursday, November 7th. The company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.31). Kadmon had a negative net margin of 9,855.14% and a negative return on equity of 188.03%. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.29 million. On average, analysts predict that Kadmon Holdings Inc will post -0.69 EPS for the current year.

In other Kadmon news, major shareholder Perceptive Advisors Llc bought 1,470,588 shares of Kadmon stock in a transaction on Monday, November 18th. The stock was acquired at an average cost of $3.40 per share, with a total value of $4,999,999.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.85% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Meeder Asset Management Inc. boosted its position in shares of Kadmon by 736.6% in the third quarter. Meeder Asset Management Inc. now owns 9,955 shares of the company’s stock worth $25,000 after purchasing an additional 8,765 shares during the period. D. E. Shaw & Co. Inc. bought a new position in shares of Kadmon in the second quarter worth approximately $27,000. Parametric Portfolio Associates LLC bought a new position in shares of Kadmon in the second quarter worth approximately $30,000. California Public Employees Retirement System bought a new position in shares of Kadmon in the third quarter worth approximately $56,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Kadmon by 47.0% in the second quarter. JPMorgan Chase & Co. now owns 35,761 shares of the company’s stock worth $70,000 after purchasing an additional 11,435 shares during the period. 76.96% of the stock is owned by institutional investors and hedge funds.

About Kadmon (NYSE:KDMN)

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Featured Story: Cash Flow

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.